FDA approves pembrolizumab as first-line combination therapy with pemetrexed and carboplatin for metastatic non-squamous NSCLC irrespective of PD-l1 expression

24th May 2017 Uncategorised 0

European Society for Medical Oncology News

More: FDA approves pembrolizumab as first-line combination therapy with pemetrexed and carboplatin for metastatic non-squamous NSCLC irrespective of PD-l1 expression
Source: MDlinx